Journal List > Korean J Urogenit Tract Infect Inflamm > v.8(2) > 1059914

TOOLS
Cho, Kim, Kim, Kim, Lee, and Min: Prevalence of Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium, Ureaplasma urealyticum in Chronic Prostatitis Category IIIa and IIIb Patients Using Polymerase Chain Reaction
Original Article

Korean J Urogenit Tract Infect Inflamm 2013;8(2):102-108.

Published online: 17 October 2013

DOI: https://doi.org/10.14777/kjutii.2013.8.2.102

Prevalence of Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium, Ureaplasma urealyticum in Chronic Prostatitis Category IIIa and IIIb Patients Using Polymerase Chain Reaction

In-Chang Cho, Yoo Seok Kim, Sung Bin Kim, Soon Ki Kim, Gyeong In Lee1, Seung Ki Min

Department of Urology, National Police Hospital, Seoul, Korea

1Department of Laboratory Medicine, National Police Hospital, Seoul, Korea

Correspondence to: Seung Ki Min, Department of Urology, National Police Hospital, 123, Songi-ro, Songpa-gu, Seoul 138-708, Korea Tel: +82-2-3400-1264, Fax: +82-2-3400-1259 E-mail: msk0701@hanmail.net

No potential conflict of interest relevant to this article was reported.

Received 30 September 2013       Revised 14 October 2013       Accepted 14 October 2013

Copyright © 2013 Korean Association of Urogenital Tract Infection and Inflammation

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose

The aim of this study was to report on the prevalence of Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Mycoplasma genitalium (MG), and Ureaplasma urealyticum (UU) in patients with chronic prostatitis (CP) IIIa and CP IIIb using PCR and correlations between four microorganisms and other clinical parameters.

Materials and Methods

The medical charts of 206 Patients who visited National Police Hospital and were diagnosed with CP IIIa and CP IIIb between January 2011 and December 2012 were reviewed. We investigated white blood cell (WBC) counts on expressed prostatic secretion (EPS) samples and the frequency of four possible causative microorganisms of prostatitis, CT, NG, MG, and UU, using PCR techniques on first voided urine samples (VB1).

Results

Of 206 patients, 88 patients were CP IIIa and 118 were CP IIIb, with a mean age of 33.8±12.9 and 34.6±11.3, respectively. CT, NG, MG, and UU were detected in 13.6%, 0%, 4.5%, and 14.8% of CP IIIa patients and in 0.8%, 0%, 3.4%, and 11.9% of CP IIIb patients, respectively. Among men aged 19-30, detection of CT was significantly greater in the CP IIIa group than in the CP IIIb group (p=0.002). CT showed a positive association with EPS or the third voided urine (VB3) WBC count grade (p<0.01), however, MG and UU did not. The relationship between numbers of detected microorganisms and WBC counts was statistically insignificant.

Conclusions

In subgroup analyses, microorganisms were detected in by PCR in 29 CP IIIa patients (32.9%) and 19 CP IIIb patients (16.1%). Young aged men in the CP IIIa group showed high prevalence of CT, and patients in whom CT was detected in urine PCR had high EPS WBC counts.

Keywords: Polymerase chain reaction, Prevalence, Chlamydia

REFERENCES

1. Ku JH, Lee SH, Jeon YS, Kim ME, Lee NK, Park YH. Epidemiologic study of chronic prostatitis-like symptoms surveyed among young men in the area of Taejeon and Chungnam: prevalence and influence of weather. Korean J Urol. 2002; 43:318–21.
2. Shoskes DA, Landis JR, Wang Y, Nickel JC, Zeitlin SI, Nadler R. Chronic Prostatitis Collaborative Research Network Study Group. Impact of post-ejaculatory pain in men with category III chronic prostatitis/chronic pelvic pain syndrome. J Urol. 2004; 172:542–7.
crossref
3. Krieger JN, Egan KJ, Ross SO, Jacobs R, Berger RE. Chronic pelvic pains represent the most prominent urogenital symptoms of “chronic prostatitis”. Urology. 1996; 48:715–21.
crossref
4. Pontari MA. Chronic prostatitis/chronic pelvic pain syndrome. Urol Clin North Am. 2008; 35:81–9.
crossref
5. Schaeffer AJ. Epidemiology and evaluation of chronic pelvic pain syndrome in men. Int J Antimicrob Agents. 2008; 31(Suppl 1):S108–11.
crossref
6. Cho IC, Min SK. Asymptomatic prostatitis: clinical significances and management. Korean J Urogenit Tract Infect Inflamm. 2013; 8:13–9.
crossref
7. Nickel JC, Nyberg LM, Hennenfent M. Research guidelines for chronic prostatitis: consensus report from the first National Institutes of Health International Prostatitis Collaborative Network. Urology. 1999; 54:229–33.
crossref
8. Nickel JC, Downey J, Hunter D, Clark J. Prevalence of prostatitis-like symptoms in a population based study using the National Institutes of Health chronic prostatitis symptom index. J Urol. 2001; 165:842–5.
crossref
9. Nadler RB, Schaeffer AJ. Lower urinary tract cultures. Nickel JC, editor. Textbook of prostatitis. 1st ed.Oxford, England: Isis Medical Media;1999. p. 201–6.
10. Schaeffer AJ, Landis JR, Knauss JS, Propert KJ, Alexander RB, Litwin MS, et al. Chronic Prostatitis Collaborative Research Network Group. Demographic and clinical characteristics of men with chronic prostatitis: the national institutes of health chronic prostatitis cohort study. J Urol. 2002; 168:593–8.
crossref
11. Krieger JN, Riley DE. Chronic prostatitis: charlottesville to Seattle. J Urol. 2004; 172:2557–60.
crossref
12. de la Rosette JJ, Hubregtse MR, Karthaus HF, Debruyne FM. Results of a questionnaire among Dutch urologists and general practitioners concerning diagnostics and treatment of patients with prostatitis syndromes. Eur Urol. 1992; 22:14–9.
crossref
13. Moon TD. Questionnaire survey of urologists and primary care physicians' diagnostic and treatment practices for prostatitis. Urology. 1997; 50:543–7.
crossref
14. Lee KS, Choi JD. Chronic prostatitis: approaches for best management. Korean J Urol. 2012; 53:69–77.
crossref
15. Johnson RE, Green TA, Schachter J, Jones RB, Hook EW 3rd, Black CM, et al. Evaluation of nucleic acid amplification tests as reference tests for Chlamydia trachomatis infections in asymptomatic men. J Clin Microbiol. 2000; 38:4382–6.
16. Kim TH, Kim TH, Kim HR, Lee MK, Myung SC, Kim YS. Detection of cryptic microorganisms in patients with chronic prostatitis by multiplex polymerase chain reaction. Korean J Urol. 2007; 48:304–9.
crossref
17. Seo KI, Hwang JC, Kim TW, Lee SH, Park SY, Roh SH. Results of microorganism detection by multiplex polymerase chain reaction in patients with chronic pelvic pain syndrome. Korean J Urol. 2009; 50:1120–4.
crossref
18. Krieger JN, Nyberg L Jr, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA. 1999; 282:236–7.
crossref
19. Kim SW, Lee JY, Park WJ, Cho YH, Yoon MS. The diagnostic values of the polymerase chain reaction in prostatitis. Korean J Infect Dis. 2000; 32:265–73.
20. Ha JS, Kim SW, Cho YH. Detection of cryptic microorganisms by polymerase chain reaction assay in chronic pelvic pain syndrome. Korean J Urol. 2002; 43:396–401.
21. Krieger JN, Riley DE, Roberts MC, Berger RE. Prokaryotic DNA sequences in patients with chronic idiopathic prostatitis. J Clin Microbiol. 1996; 34:3120–8.
crossref
22. Brookings C, Goldmeier D, Sadeghi-Nejad H. Sexually transmitted infections and sexual function in relation to male fertility. Korean J Urol. 2013; 54:149–56.
crossref
23. Mouton JW, Verkooyen R, van der Meijden WI, van Rijsoort-Vos TH, Goessens WH, Kluytmans JA, et al. Detection of Chlamydia trachomatis in male and female urine specimens by using the amplified Chlamydia trachomatis test. J Clin Microbiol. 1997; 35:1369–72.
crossref
24. Lee YS, Lee KS. Chlamydia and male lower urinary tract diseases. Korean J Urol. 2013; 54:73–7.
25. Kim SJ, Lee DS, Lee SJ. The prevalence and clinical significance of urethritis and cervicitis in asymptomatic people by use of multiplex polymerase chain reaction. Korean J Urol. 2011; 52:703–8.
crossref

Fig. 1.
(A) Detected microorganisms according to age subgroup in CP IIIa and CP IIIb patients (age 19-30 years). (B) Detected microorganisms according to age subgroup in CP IIIa and CP IIIb patients (age 31-40 years). (C) Detected microorganisms according to age subgroup in CP IIIa and CP IIIb patients (age 41-50 years). (D) Detected microorganisms according to age subgroup in CP IIIa and CP IIIb patients (age 51-60 years). CT: Chlamydia trachomatis, MG: Mycoplasma genitalium, UU: Ureaplasma urealyticum.
kjutii-8-102f1.tif
Fig. 2.
Positivity of microorganisms according to WBC counts in EPS or VB3. CT: Chlamydia trachomatis, MG: Mycoplasma genitalium, UU: Ureaplasma urealyticum, WBC: white blood cell, EPS: expressed prostatic secretion, HPF: high power field.
kjutii-8-102f2.tif
Table 1.
Baseline characteristics of CPIIIa and CP IIIb patients (n=206)
  CP IIIa (n=88) CP IIIb (n=118)
Age (year) 33.8±12.9 34.6±11.3
CT positivity 12 (13.6) 1 (0.8)
NG positivity 0 (0) 0 (0)
MG positivity 4 (4.5) 4 (3.4)
UU positivity 13 (14.8) 14 (11.9)

Values are presented as mean±standard deviation or number (%). CP: chronic prostatitis, CT: Chlamydia trachomatis, NG: Neisseria gonorrhoeae, MG: Mycoplasma genitalium, UU: Ureaplasma urealyticum. Positivity for microorganisms was detected using polymerase chain reaction methods in urine samples.

Table 2.
Number of detected microorganism according to WBC counts in EPS or VB3
Number of microorganisms WBC counts p-value
0-2 3-5 6-8 10-15 20-25 Many
0 49/58 (84.5) 29/35 (82.9) 22/25 (88.0) 13/17 (76.5) 12/18 (66.7) 38/53 (71.7) 0.205
1 9/58 (15.5) 6/35 (17.1) 2/25 (8.0) 4/17 (23.5) 6/18 (33.3) 11/53 (20.8)  
2 0/58 (0.0) 0/35 (0.0) 1/25 (4.0) 0/17 (0.0) 0/18 (0.0) 4/53 (7.5)  
3 0/58 (0.0) 0/35 (0.0) 0/25 (0.0) 0/17 (0.0) 0/18 (0.0) 0/53 (0.0)  
4 0/58 (0.0) 0/35 (0.0) 0/25 (0.0) 0/17 (0.0) 0/18 (0.0) 0/53 (0.0)  

Values are presented as number/HPF (%).WBC: white blood cell, EPS: expressed prostatic secretion, HPF: high power field.

TOOLS
Similar articles